Cargando…
Perspective: cancer vaccines in the era of immune checkpoint blockade
Current excitement about cancer immunotherapy is the result of unprecedented clinical impact from immune checkpoint inhibitors, particularly those that target programmed death (PD)-1 and PD-ligand (L)-1. Numerous other immunotherapeutics are also finding their way into the clinic either alone or in...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267701/ https://www.ncbi.nlm.nih.gov/pubmed/30446791 http://dx.doi.org/10.1007/s00335-018-9786-z |
_version_ | 1783376135689601024 |
---|---|
author | Cebon, Jonathan |
author_facet | Cebon, Jonathan |
author_sort | Cebon, Jonathan |
collection | PubMed |
description | Current excitement about cancer immunotherapy is the result of unprecedented clinical impact from immune checkpoint inhibitors, particularly those that target programmed death (PD)-1 and PD-ligand (L)-1. Numerous other immunotherapeutics are also finding their way into the clinic either alone or in combination, and these have potential applications in many cancer types. Therapeutic cancer vaccines have been a major focus for many pioneers in the field yet have largely failed to live up to expectations as game-changing immunotherapeutics. This, despite decades of focussed efforts that have identified antigens, optimised adjuvants and refined approaches to pre-clinical modelling and clinical monitoring. If antigen-directed immunotherapeutics are to take a place in the anti-cancer therapeutic armamentarium, it will be crucial to understand the potential niche that could be occupied by cancer vaccines that can specifically induce or modify immune response against cancer antigens. |
format | Online Article Text |
id | pubmed-6267701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-62677012018-12-18 Perspective: cancer vaccines in the era of immune checkpoint blockade Cebon, Jonathan Mamm Genome Article Current excitement about cancer immunotherapy is the result of unprecedented clinical impact from immune checkpoint inhibitors, particularly those that target programmed death (PD)-1 and PD-ligand (L)-1. Numerous other immunotherapeutics are also finding their way into the clinic either alone or in combination, and these have potential applications in many cancer types. Therapeutic cancer vaccines have been a major focus for many pioneers in the field yet have largely failed to live up to expectations as game-changing immunotherapeutics. This, despite decades of focussed efforts that have identified antigens, optimised adjuvants and refined approaches to pre-clinical modelling and clinical monitoring. If antigen-directed immunotherapeutics are to take a place in the anti-cancer therapeutic armamentarium, it will be crucial to understand the potential niche that could be occupied by cancer vaccines that can specifically induce or modify immune response against cancer antigens. Springer US 2018-11-16 2018 /pmc/articles/PMC6267701/ /pubmed/30446791 http://dx.doi.org/10.1007/s00335-018-9786-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Cebon, Jonathan Perspective: cancer vaccines in the era of immune checkpoint blockade |
title | Perspective: cancer vaccines in the era of immune checkpoint blockade |
title_full | Perspective: cancer vaccines in the era of immune checkpoint blockade |
title_fullStr | Perspective: cancer vaccines in the era of immune checkpoint blockade |
title_full_unstemmed | Perspective: cancer vaccines in the era of immune checkpoint blockade |
title_short | Perspective: cancer vaccines in the era of immune checkpoint blockade |
title_sort | perspective: cancer vaccines in the era of immune checkpoint blockade |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267701/ https://www.ncbi.nlm.nih.gov/pubmed/30446791 http://dx.doi.org/10.1007/s00335-018-9786-z |
work_keys_str_mv | AT cebonjonathan perspectivecancervaccinesintheeraofimmunecheckpointblockade |